Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Document › Details

McDermott Will & Emery. (1/9/17). "Press Release: McDermott Will & Emery Advised Servier in Its Strategic Immuno-oncology Co-development Alliance with Pieris Pharmaceuticals". Paris.

Organisations Organisation McDermott Will & Emery, Paris
  Today McDermott Will & Emery (MWE) (Group)
  Group McDermott Will & Emery (MWE) (Group)
  Organisation 2 Pieris Pharmaceuticals Inc. (Nasdaq: PIRS)
  Group Pieris (Group)
Products Product legal services
  Product 2 PRS-332 (anti-PD-1 Anticalin, Pieris / Servier)
Index terms Index term Servier–McDermott Will & Emery: legal services, 201701 advisor immuno-oncology co-developm agreem of Servier with Pieris Pharmaceuticals
  Index term 2 Servier–Pieris: cancer immunotherapy, 201701– collab €30m upfront + milestones to develop bi-specific ABs using Anticalin technology incl PRS-322

International law firm McDermott Will & Emery advised French-based Servier, an international pharmaceutical company, in its strategic immuno-oncology co-development alliance with Pieris Pharmaceuticals, a clinical-stage biotechnology company, allowing both companies to bring innovative solutions to cancer patients.

The collaboration includes four additional bispecific programs and may be expanded to a total of eight immuno-oncology programs (including PRS-332). Pieris and Servier will jointly develop PRS-332 and split commercial rights geographically, with Pieris retaining all commercial rights in the United States and Servier having commercial rights in the rest of the world.

This alliance will significantly enhance Servier’s portfolio in immuno-oncology, which already comprises 5 products in late preclinical or early development.

The financial terms of the collaboration include an upfront payment to Pieris of EUR30 million (approximately US$31.3 million). Pieris may also receive FTE funding for specific projects, an option fee upon potential expansion of the collaboration as well as development-dependent and commercial milestone payments for PRS-332 and each additional program. The total development, regulatory and sales-based milestone payments to Pieris could reach EUR324 million (approximately US$338 million) for PRS-332, and up to EUR193 million (approximately US$201 million) for each of the other programs.

Pieris and Servier will share preclinical and clinical development costs for each co-developed program. In addition, Pieris will be entitled to receive tiered royalties up to low double digits on the sales of commercialized products in the Servier territories.

The McDermott team advising on the transaction comprised of Paris-based partners Emmanuelle Trombe and Anthony Paronneau, along with associate Christine Wahr.

About McDermott Will & Emery

McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,100 lawyers, we have offices in Boston, Brussels, Chicago, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.

Related Professionals

Anthony Paronneau
Partner Paris
Emmanuelle Trombe
Partner Paris
Christine M. Wahr
Associate Boston

Related Experience

Corporate & Transactional
Life Sciences
Licensing & Collaborative Arrangements

Record changed: 2023-06-05


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

More documents for McDermott Will & Emery (MWE) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px

» top